Chimera blog: biotech law and policy

News, discussion, and analysis of law and policy affecting the US biotech sector

Pages

Home
Case Law Index
Mythology
Disclaimer

Case Law Index

Biotech case law index

This page is under construction

Email This BlogThis!Share to X Share to Facebook Share to Pinterest

Subscribe to: Posts (Atom)

About Me

Farid: Farid Zakaria is an attorney based in Los Angeles and is interested in the intersection of law, technology, and society. Suggestions? Contact me at farid.zakaria7@gmail.com.

View my complete profile

Labels

America Invents Act big pharma BIO Biologics Price Competition Act bioterrorism blood stem cells business Congress criminal law data exclusivity deficit reduction DNA arrestee laws DNA sequencing employment evergreening FDA follow-on biologics Fourth Amendment gene patents generics genetic testing genomics Hatch-Waxman Act innovation policy international patent policy investment legislation lobbying NAFTA National Bioeconomy Blueprint NOTA patent law pay-for-delay agreements PDUFA personalized medicine privacy research safety tax policy trade secrets law TRIPS tropical diseases whole genome sequencing WIPO

Blog Archive

▼ 2012 (5)
- ▼ October (1)
  - Investment analyst predicts explosive biotech growth
- ► April (1)
- ► February (1)
- ► January (2)

► 2011 (13)
- ► December (13)

Search This Blog

Biotech Blogs

BioLaw: Law and the Life Sciences
Genomics Law Report
Holman's Biotech IP Blog
Patent Baristas
Patent Docs
The IN VIVO Blog

Followers

Popular Posts

CRS report discusses role of trade secret law in innovation policy
Appeals court upholds California law requiring arrestees to give DNA sample
Gene patents won't impede whole genome sequencing, law professor says
White House launches initiatives to spur biotech innovation, receives input from stakeholders on National Bioeconomy Blueprint
Obama proposes plan to ban pay-for-delay agreements, cut exclusivity period for biologics to 7 years
FDA drug safety decision may have been influenced by big pharma
Advances in DNA technology hold great promises and... threats
Big Pharma relying on deals with small biotech firms in the wake of financial crisis
WIPO launches new consortium offering IP for fight against tropical diseases
Bitech sector seen as recession proof

Picture Window theme. Powered by Blogger.